Eli Lilly and Company reports that it will invest more than $470 million to build a new parenteral (injectable) product and delivery device manufacturing facility in North Carolina’s Research Triangle Park.

The new manufacturing site will be a facility that produces parenteral (or injectable) products and delivery devices. To operate the site, Lilly plans to create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations. Lilly currently has seven manufacturing sites located in the US at sites in Indiana, New Jersey, and Puerto Rico.

Lilly’s project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee. The company’s JDIG agreement lists its investment target as $474 million. State payments only occur following performance verification by the Departments of Commerce and Revenue that the company has met its incremental job creation and investment targets.

Source: Eli Lilly and Company